[go: up one dir, main page]

WO2011014299A3 - Identification et utilisation de petites molécules visant à moduler le fonctionnement des facteurs de transcription et à traiter les maladies associées aux facteurs de transcription - Google Patents

Identification et utilisation de petites molécules visant à moduler le fonctionnement des facteurs de transcription et à traiter les maladies associées aux facteurs de transcription Download PDF

Info

Publication number
WO2011014299A3
WO2011014299A3 PCT/US2010/037664 US2010037664W WO2011014299A3 WO 2011014299 A3 WO2011014299 A3 WO 2011014299A3 US 2010037664 W US2010037664 W US 2010037664W WO 2011014299 A3 WO2011014299 A3 WO 2011014299A3
Authority
WO
WIPO (PCT)
Prior art keywords
transcription factor
target
function
small molecules
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/037664
Other languages
English (en)
Other versions
WO2011014299A2 (fr
Inventor
Peter Oettgen
Alan C. Rigby
Towia Libermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of WO2011014299A2 publication Critical patent/WO2011014299A2/fr
Publication of WO2011014299A3 publication Critical patent/WO2011014299A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Library & Information Science (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Computing Systems (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés d'identification d'agents d'intérêt potentiel se présentant sous la forme de petites molécules et capables de moduler le fonctionnement des facteurs de transcription, par exemple le fonctionnement/l'expression d'un facteur de transcription cible et/ou de protéines situées en aval de ladite protéine cible. Lesdits procédés d'identification comprennent le criblage de banques de petites molécules grâce à l'arrimage moléculaire in silico à haut rendement de petites molécules/agents d'intérêt potentiel qui sont sélectivement identifiés pour leur capacité à cibler et à perturber l'interface facteur de transcription-ADN grâce à un unique facteur de transcription et/ou à des descripteurs d'ADN définis au sein d'un pharmacophore, cela étant suivi de l'essai/évaluation des agents d'intérêt potentiel identifiés ci-dessus grâce à un ou plusieurs dosages in vitro visant à évaluer leur capacité à moduler le fonctionnement des facteurs de transcription, dont l'expression de cette protéine et/ou de ces protéines cibles situées en aval du facteur de transcription cible. La présente invention concerne également divers composés décrits ici (par exemple un composé de formule XI), leurs sels pharmaceutiquement acceptables et des procédés d'utilisation des composés tels que décrits ici.
PCT/US2010/037664 2009-06-05 2010-06-07 Identification et utilisation de petites molécules visant à moduler le fonctionnement des facteurs de transcription et à traiter les maladies associées aux facteurs de transcription Ceased WO2011014299A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18464709P 2009-06-05 2009-06-05
US61/184,647 2009-06-05

Publications (2)

Publication Number Publication Date
WO2011014299A2 WO2011014299A2 (fr) 2011-02-03
WO2011014299A3 true WO2011014299A3 (fr) 2011-04-21

Family

ID=43529910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/037664 Ceased WO2011014299A2 (fr) 2009-06-05 2010-06-07 Identification et utilisation de petites molécules visant à moduler le fonctionnement des facteurs de transcription et à traiter les maladies associées aux facteurs de transcription

Country Status (1)

Country Link
WO (1) WO2011014299A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108872442B (zh) * 2018-08-17 2021-04-27 无限极（中国）有限公司 一种基于谱效关系的骨胶原肽质量检测方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453640B2 (en) 2018-03-21 2022-09-27 Northwestern University Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy
US20220041591A1 (en) * 2018-10-19 2022-02-10 Auckland Uniservices Limited Compounds for treating diabetes and/or related conditions
CN111072652B (zh) * 2018-10-19 2023-05-23 暨南大学 用于治疗糖尿病和/或相关病症的化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084115A1 (en) * 2004-02-09 2006-04-20 The Regents Of The University Of California Selective high affinity polydentate ligands and methods of making such
WO2008057556A2 (fr) * 2006-11-06 2008-05-15 Beth Israel Deaconess Medical Center Identification et utilisation de petites molécules pour moduler la fonction du facteur de transcription ese-1 et pour traiter les maladies associées au facteur de transcription ese-1
WO2008057555A2 (fr) * 2006-11-06 2008-05-15 Beth Israel Deaconess Medical Center Identification et utilisation de petites molécules pour moduler la fonction du facteur de transcription pdef et pour traiter les maladies associées au facteur de transcription pdef
WO2008066672A2 (fr) * 2006-11-06 2008-06-05 Beth Israel Deaconess Medical Center Identification et utilisation de petites molécules pour moduler une fonction de facteur de transcription et pour traiter des maladies associées à un facteur de transcription

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084115A1 (en) * 2004-02-09 2006-04-20 The Regents Of The University Of California Selective high affinity polydentate ligands and methods of making such
WO2008057556A2 (fr) * 2006-11-06 2008-05-15 Beth Israel Deaconess Medical Center Identification et utilisation de petites molécules pour moduler la fonction du facteur de transcription ese-1 et pour traiter les maladies associées au facteur de transcription ese-1
WO2008057555A2 (fr) * 2006-11-06 2008-05-15 Beth Israel Deaconess Medical Center Identification et utilisation de petites molécules pour moduler la fonction du facteur de transcription pdef et pour traiter les maladies associées au facteur de transcription pdef
WO2008066672A2 (fr) * 2006-11-06 2008-06-05 Beth Israel Deaconess Medical Center Identification et utilisation de petites molécules pour moduler une fonction de facteur de transcription et pour traiter des maladies associées à un facteur de transcription

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108872442B (zh) * 2018-08-17 2021-04-27 无限极（中国）有限公司 一种基于谱效关系的骨胶原肽质量检测方法

Also Published As

Publication number Publication date
WO2011014299A2 (fr) 2011-02-03

Similar Documents

Publication Publication Date Title
WO2008066672A3 (fr) Identification et utilisation de petites molécules pour moduler une fonction de facteur de transcription et pour traiter des maladies associées à un facteur de transcription
WO2008057556A3 (fr) Identification et utilisation de petites molécules pour moduler la fonction du facteur de transcription ese-1 et pour traiter les maladies associées au facteur de transcription ese-1
Sobotzki et al. HATRIC-based identification of receptors for orphan ligands
Wu et al. A chemical proteomics approach for global analysis of lysine monomethylome profiling
Tan Diversity-oriented synthesis: exploring the intersections between chemistry and biology
EP1994142A4 (fr) Procédés et compositions permettant d'isoler rapidement de petites molécules d'arn
Scholes et al. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
Wang et al. Antibody-free approach for the global analysis of protein methylation
Krautkramer et al. Quantification of SAHA-dependent changes in histone modifications using data-independent acquisition mass spectrometry
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
WO2009067546A3 (fr) Marqueurs de cancer du poumon et leurs utilisations
AR063840A1 (es) Anticuerpos humanos monoclonales para btla y metodos de uso
BRPI0717768A2 (pt) Anticorpo, epítipo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
NO20075635L (no) Antigenbindende molekyler som har modifiserte Fc-regioner og endret binding til Fc-reseptorer
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
Allen et al. Inhibition of histone binding by supramolecular hosts
WO2008039769A3 (fr) Procédés et dispositifs pour analyser de petites molécules d'arn
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
WO2007114986A3 (fr) Sondes coopératives et leurs procédés d'utilisation
Lu-Culligan et al. Acetyl-methyllysine marks chromatin at active transcription start sites
WO2011014299A3 (fr) Identification et utilisation de petites molécules visant à moduler le fonctionnement des facteurs de transcription et à traiter les maladies associées aux facteurs de transcription
Hamajima et al. Site-selective synthetic acylation of a target protein in living cells promoted by a chemical catalyst/donor system
WO2008074029A3 (fr) Profil de protéine pour ostéoarthrite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10804850

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012514230

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 10804850

Country of ref document: EP

Kind code of ref document: A2